Middle East and Africa Hereditary Transthyretin Amyloidosis Market

PUBLISHED: August 1, 2023

PAGES: 113 Pages

DELIVERY TIME: Inquiry

ADD TO COMPARE

SELECT AN OPTION

The Middle East and Africa hereditary transthyretin amyloidosis market is expected to reach USD 10, 65,985.45 thousand by 2030 from USD 51,673.84 thousand in 2022, growing at a CAGR of 3.1% in the forecast period of 2023 to 2030.

Market Segmentation

Middle East and Africa Hereditary Transthyretin Amyloidosis Market, By Diagnosis and Treatment (Diagnosis and Treatment), Gene Variation (V122L, T60A, V30M, and Others), Gender (Male and Female), Indication (Cardiomyopathy (ATTR-CM), Polyneuropathy (ATTR-PN), and Mixed Indications), End-User (Hospitals and Clinics, Diagnostic Laboratories, Radiology Centers, Academic and Research Institutes, Ambulatory Surgical Centers, and Homecare) Distribution Channel (Direct Tender, Third Party Distributors, Hospital Pharmacy, Retail Pharmacy, and Others), Country (South Africa, U.A.E., Egypt, Saudi Arabia, Kuwait, and Rest of the Middle East and Africa) - Industry Trends and Forecast to 2030.

Overview of Middle East and Africa Hereditary Transthyretin Amyloidosis Market Dynamics

Driver
Rising prevalence of hereditary transthyretin amyloidosis
Restraint
Stringent regulatory approvals for hereditary transthyretin amyloidosis
Opportunity
Government initiatives for hereditary transthyretin amyloidosis

Market Players

Some of the key market players operating in the Middle East and Africa hereditary transthyretin amyloidosis market are:

Pfizer Inc.
Koninklijke Philips N.V.
Siemens Healthcare GmbH
CANON MEDICAL SYSTEMS CORPORATION
MinFound Medical Systems Co.
Alnylam Pharmaceuticals, Inc.
NIHON KOHDEN CORPORATION.
GE HealthCare.(A Subsidary of General Electric)
FONAR Corp.
Neusoft Corporation
Shimadzu Corporation
SCHILLER
Novo Nordisk A/S
AstraZeneca

1 INTRODUCTION 14

1.1 OBJECTIVES OF THE STUDY 14
1.2 MARKET DEFINITION 14
1.3 OVERVIEW OF THE MIDDLE EAST AND AFRICA HEREDITARY TRANSTHYRETIN AMYLOIDOSIS MARKET 14
1.4 LIMITATIONS 16
1.5 MARKETS COVERED 16

2 MARKET SEGMENTATION 19

2.1 MARKETS COVERED 19
2.2 GEOGRAPHICAL SCOPE 20
2.3 YEARS CONSIDERED FOR THE STUDY 20
2.4 CURRENCY AND PRICING 20
2.5 DBMR TRIPOD DATA VALIDATION MODEL 21
2.6 MULTIVARIATE MODELLING 24
2.7 DIAGNOSIS AND TREATMENT LIFELINE CURVE 24
2.8 PRIMARY INTERVIEWS WITH KEY OPINION LEADERS 25
2.9 DBMR MARKET POSITION GRID 26
2.10 MARKET END-USER COVERAGE GRID 27
2.11 VENDOR SHARE ANALYSIS 28
2.12 SECONDARY SOURCES 29
2.13 ASSUMPTIONS 29

3 EXECUTIVE SUMMARY 30

4 PREMIUM INSIGHTS 32

4.1 PESTEL'S MODEL 33
4.2 PORTER'S 5 FORCES 34
4.3 PIPELINE ANALYSIS 35

5 REGULATORY SCENARIO 36

6 MARKET OVERVIEW 38

6.1 DRIVERS 40
- 6.1.1 RISING PREVALENCE OF HEREDITARY TRANSTHYRETIN AMYLOIDOSIS 40
- 6.1.2 INCREASING RESEARCH AND CLINICAL TRIALS FOR HEREDITARY TRANSTHYRETIN AMYLOIDOSIS 40
- 6.1.3 ADVANCEMENT IN GENE THERAPY 41
6.2 RESTRAINTS 42
- 6.2.1 STRINGENT REGULATORY APPROVALS FOR HEREDITARY TRANSTHYRETIN AMYLOIDOSIS TREATMENT 42
- 6.2.2 HIGH COST ASSOCIATED WITH HEREDITARY TRANSTHYRETIN AMYLOIDOSIS TREATMENT 43
6.3 OPPORTUNITIES 44
- 6.3.1 GOVERNMENT INITIATIVES FOR HEREDITARY TRANSTHYRETIN AMYLOIDOSIS TREATMENT 44
- 6.3.2 STRATEGIC INITIATIVES BY THE MARKET PLAYERS 45
6.4 CHALLENGES 46
- 6.4.1 COMPLEXITY IN DIAGNOSING HEREDITARY TRANSTHYRETIN AMYLOIDOSIS 46
- 6.4.2 LIMITED PATIENT POOL FOR HEREDITARY TRANSTHYRETIN AMYLOIDOSIS 47

7 MIDDLE EAST AND AFRICA HEREDITARY TRANSTHYRETIN AMYLOIDOSIS MARKET : BY COUNTRIES 48

8 MIDDLE EAST AND AFRICA HEREDITARY TRANSTHYRETIN AMYLOIDOSIS MARKET, COMPANY LANDSCAPE 81

8.1 COMPANY SHARE ANALYSIS: MIDDLE EAST AND AFRICA 81

9 SWOT ANALYSIS 82

10 COMPANY PROFILE 83

10.1 PFIZER INC. 83
- 10.1.1 COMPANY SNAPSHOT 83
- 10.1.2 REVENUE ANALYSIS 83
- 10.1.3 PRODUCT PORTFOLIO 84
- 10.1.4 RECENT DEVELOPMENT 84
10.2 GE HEALTHCARE.( A SUBSIDARY OF GENERAL ELECTRIC) 85
- 10.2.1 COMPANY SNAPSHOT 85
- 10.2.2 REVENUE ANALYSIS 85
- 10.2.3 PRODUCT PORTFOLIO 86
- 10.2.4 RECENT DEVELOPMENT 86
10.3 SIEMENS HEALTHCARE GMBH 87
- 10.3.1 COMPANY SNAPSHOT 87
- 10.3.2 REVENUE ANALYSIS 87
- 10.3.3 PRODUCT PORTFOLIO 88
- 10.3.4 RECENT DEVELOPMENT 88
10.4 KONINKLIJKE PHILIPS N.V. 89
- 10.4.1 COMPANY SNAPSHOT 89
- 10.4.2 REVENUE ANALYSIS 89
- 10.4.3 PRODUCT PORTFOLIO 90
- 10.4.4 RECENT DEVELOPMENT 90
10.5 CANON MEDICAL SYSTEMS CORPORATION 91
- 10.5.1 COMPANY SNAPSHOT 91
- 10.5.2 REVENUE ANALYSIS 91
- 10.5.3 PRODUCT PORTFOLIO 92
- 10.5.4 RECENT DEVELOPMENT 92
10.6 ALNYLAM PHARMACEUTICALS, INC. 93
- 10.6.1 COMPANY SNAPSHOT 93
- 10.6.2 REVENUE ANALYSIS 93
- 10.6.3 PRODUCT PORTFOLIO 94
- 10.6.4 RECENT DEVELOPMENT 94
10.7 ASTRAZENECA 95
- 10.7.1 COMPANY SNAPSHOT 95
- 10.7.2 REVENUE ANALYSIS 95
- 10.7.3 PRODUCT PORTFOLIO 96
- 10.7.4 RECENT DEVELOPMENT 96
10.8 FONAR CORP. 97
- 10.8.1 COMPANY SNAPSHOT 97
- 10.8.2 REVENUE ANALYSIS 97
- 10.8.3 PRODUCT PORTFOLIO 98
- 10.8.4 RECENT DEVELOPMENT 98
10.9 MINFOUND MEDICAL SYSTEMS CO., 99
- 10.9.1 COMPANY SNAPSHOT 99
- 10.9.2 PRODUCT PORTFOLIO 99
- 10.9.3 RECENT DEVELOPMENT 99
10.10 NEUSOFT CORPORATION 100
- 10.10.1 COMPANY SNAPSHOT 100
- 10.10.2 REVENUE ANALYSIS 100
- 10.10.3 PRODUCT PORTFOLIO 101
- 10.10.4 RECENT DEVELOPMENT 101
10.11 NIHON KOHDEN CORPORATION. 102
- 10.11.1 COMPANY SNAPSHOT 102
- 10.11.2 RECENT FINANCIALS 102
- 10.11.3 PRODUCT PORTFOLIO 103
- 10.11.4 RECENT DEVELOPMENT 103
10.12 NOVO NORDISK A/S 104
- 10.12.1 COMPANY SNAPSHOT 104
- 10.12.2 REVENUE ANALYSIS 104
- 10.12.3 PRODUCT PORTFOLIO 105
- 10.12.4 RECENT DEVELOPMENT 105
10.13 SCHILLER 106
- 10.13.1 COMPANY SNAPSHOT 106
- 10.13.2 PRODUCT PORTFOLIO 106
- 10.13.3 RECENT DEVELOPMENT 106
10.14 SHIMADZU CORPORATION 107
- 10.14.1 COMPANY SNAPSHOT 107
- 10.14.2 REVENUE ANALYSIS 107
- 10.14.3 PRODUCT PORTFOLIO 108
- 10.14.4 RECENT DEVELOPMENT 108

11 QUESTIONNAIRE 109

12 RELATED REPORTS 113

LIST OF TABLES

TABLE 1 MIDDLE EAST AND AFRICA HEREDITARY TRANSTHYRETIN AMYLOIDOSIS MARKET, PIPELINE ANALYSIS 35
TABLE 2 MIDDLE EAST AND AFRICA HEREDITARY TRANSTHYRETIN AMYLOIDOSIS MARKET, BY COUNTRY, 2021-2030 (USD THOUSAND) 50
TABLE 3 MIDDLE EAST AND AFRICA HEREDITARY TRANSTHYRETIN AMYLOIDOSIS MARKET, BY DIAGNOSIS AND TREATMENT, 2021-2030 (USD THOUSAND) 50
TABLE 4 MIDDLE EAST AND AFRICA DIAGNOSIS IN HEREDITARY TRANSTHYRETIN AMYLOIDOSIS MARKET, BY TESTS, 2021-2030 (USD THOUSAND) 50
TABLE 5 MIDDLE EAST AND AFRICA IMAGING TEST IN HEREDITARY TRANSTHYRETIN AMYLOIDOSIS MARKET, BY TYPE, 2021-2030 (USD THOUSAND) 50
TABLE 6 MIDDLE EAST AND AFRICA NUCLEAR IMAGING IN HEREDITARY TRANSTHYRETIN AMYLOIDOSIS MARKET, BY IMAGING TEST, 2021-2030 (USD THOUSAND) 51
TABLE 7 MIDDLE EAST AND AFRICA BIOPSY IN HEREDITARY TRANSTHYRETIN AMYLOIDOSIS MARKET, BY TYPE, 2021-2030 (USD THOUSAND) 51
TABLE 8 MIDDLE EAST AND AFRICA TREATMENT IN HEREDITARY TRANSTHYRETIN AMYLOIDOSIS MARKET, BY TYPE, 2021-2030 (USD THOUSAND) 51
TABLE 9 MIDDLE EAST AND AFRICA MEDICATIONS IN HEREDITARY TRANSTHYRETIN AMYLOIDOSIS MARKET, BY APPROVAL, 2021-2030 (USD THOUSAND) 51
TABLE 10 MIDDLE EAST AND AFRICA APPROVED MEDICATIONS IN HEREDITARY TRANSTHYRETIN AMYLOIDOSIS MARKET, BY TYPE, 2021-2030 (USD THOUSAND) 52
TABLE 11 MIDDLE EAST AND AFRICA PIPELINE MEDICATIONS IN HEREDITARY TRANSTHYRETIN AMYLOIDOSIS MARKET, BY TYPE, 2021-2030 (USD THOUSAND) 52
TABLE 12 MIDDLE EAST AND AFRICA MEDICATIONS IN HEREDITARY TRANSTHYRETIN AMYLOIDOSIS MARKET, BY MODE OF ACTION, 2021-2030 (USD THOUSAND) 52
TABLE 13 MIDDLE EAST AND AFRICA GENE SILENCER IN HEREDITARY TRANSTHYRETIN AMYLOIDOSIS MARKET, BY TYPE, 2021-2030 (USD THOUSAND) 52
TABLE 14 MIDDLE EAST AND AFRICA MEDICATIONS IN HEREDITARY TRANSTHYRETIN AMYLOIDOSIS MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD THOUSAND) 53
TABLE 15 MIDDLE EAST AND AFRICA PARENTERAL IN HEREDITARY TRANSTHYRETIN AMYLOIDOSIS MARKET, BY TYPE, 2021-2030 (USD THOUSAND) 53
TABLE 16 MIDDLE EAST AND AFRICA HEREDITARY TRANSTHYRETIN AMYLOIDOSIS MARKET, BY GENE VARIATION, 2021-2030 (USD THOUSAND) 53
TABLE 17 MIDDLE EAST AND AFRICA HEREDITARY TRANSTHYRETIN AMYLOIDOSIS MARKET, BY GENDER, 2021-2030 (USD THOUSAND) 53
TABLE 18 MIDDLE EAST AND AFRICA HEREDITARY TRANSTHYRETIN AMYLOIDOSIS MARKET, BY INDICATION, 2021-2030 (USD THOUSAND) 54
TABLE 19 MIDDLE EAST AND AFRICA POLYNEUROPATHY (ATTR-PN) IN HEREDITARY TRANSTHYRETIN AMYLOIDOSIS MARKET, BY STAGES, 2021-2030 (USD THOUSAND) 54
TABLE 20 MIDDLE EAST AND AFRICA HEREDITARY TRANSTHYRETIN AMYLOIDOSIS MARKET, BY END USER, 2021-2030 (USD THOUSAND) 54
TABLE 21 MIDDLE EAST AND AFRICA HEREDITARY TRANSTHYRETIN AMYLOIDOSIS MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD THOUSAND) 55
TABLE 22 SOUTH AFRICA HEREDITARY TRANSTHYRETIN AMYLOIDOSIS MARKET, BY DIAGNOSIS AND TREATMENT, 2021-2030 (USD THOUSAND) 55
TABLE 23 SOUTH AFRICA DIAGNOSIS IN HEREDITARY TRANSTHYRETIN AMYLOIDOSIS MARKET, BY TESTS, 2021-2030 (USD THOUSAND) 55
TABLE 24 SOUTH AFRICA IMAGING TEST IN HEREDITARY TRANSTHYRETIN AMYLOIDOSIS MARKET, BY TYPE, 2021-2030 (USD THOUSAND) 55
TABLE 25 SOUTH AFRICA NUCLEAR IMAGING IN HEREDITARY TRANSTHYRETIN AMYLOIDOSIS MARKET, BY IMAGING TEST, 2021-2030 (USD THOUSAND) 56
TABLE 26 SOUTH AFRICA BIOPSY IN HEREDITARY TRANSTHYRETIN AMYLOIDOSIS MARKET, BY TYPE, 2021-2030 (USD THOUSAND) 56
TABLE 27 SOUTH AFRICA TREATMENT IN HEREDITARY TRANSTHYRETIN AMYLOIDOSIS MARKET, BY TYPE, 2021-2030 (USD THOUSAND) 56
TABLE 28 SOUTH AFRICA MEDICATIONS IN HEREDITARY TRANSTHYRETIN AMYLOIDOSIS MARKET, BY APPROVAL, 2021-2030 (USD THOUSAND) 56
TABLE 29 SOUTH AFRICA APPROVED MEDICATIONS IN HEREDITARY TRANSTHYRETIN AMYLOIDOSIS MARKET, BY TYPE, 2021-2030 (USD THOUSAND) 57
TABLE 30 SOUTH AFRICA PIPELINE MEDICATIONS IN HEREDITARY TRANSTHYRETIN AMYLOIDOSIS MARKET, BY TYPE, 2021-2030 (USD THOUSAND) 57
TABLE 31 SOUTH AFRICA MEDICATIONS IN HEREDITARY TRANSTHYRETIN AMYLOIDOSIS MARKET, BY MODE OF ACTION, 2021-2030 (USD THOUSAND) 57
TABLE 32 SOUTH AFRICA GENE SILENCER IN HEREDITARY TRANSTHYRETIN AMYLOIDOSIS MARKET, BY TYPE, 2021-2030 (USD THOUSAND) 57
TABLE 33 SOUTH AFRICA MEDICATIONS IN HEREDITARY TRANSTHYRETIN AMYLOIDOSIS MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD THOUSAND) 58
TABLE 34 SOUTH AFRICA PARENTERAL IN HEREDITARY TRANSTHYRETIN AMYLOIDOSIS MARKET, BY TYPE, 2021-2030 (USD THOUSAND) 58
TABLE 35 SOUTH AFRICA HEREDITARY TRANSTHYRETIN AMYLOIDOSIS MARKET, BY GENE VARIATION, 2021-2030 (USD THOUSAND) 58
TABLE 36 SOUTH AFRICA HEREDITARY TRANSTHYRETIN AMYLOIDOSIS MARKET, BY GENDER, 2021-2030 (USD THOUSAND) 58
TABLE 37 SOUTH AFRICA HEREDITARY TRANSTHYRETIN AMYLOIDOSIS MARKET, BY INDICATION, 2021-2030 (USD THOUSAND) 59
TABLE 38 SOUTH AFRICA POLYNEUROPATHY (ATTR-PN) IN HEREDITARY TRANSTHYRETIN AMYLOIDOSIS MARKET, BY STAGES, 2021-2030 (USD THOUSAND) 59
TABLE 39 SOUTH AFRICA HEREDITARY TRANSTHYRETIN AMYLOIDOSIS MARKET, BY END USER, 2021-2030 (USD THOUSAND) 59
TABLE 40 SOUTH AFRICA HEREDITARY TRANSTHYRETIN AMYLOIDOSIS MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD THOUSAND) 60
TABLE 41 SAUDI ARABIA HEREDITARY TRANSTHYRETIN AMYLOIDOSIS MARKET, BY DIAGNOSIS AND TREATMENT, 2021-2030 (USD THOUSAND) 60
TABLE 42 SAUDI ARABIA DIAGNOSIS IN HEREDITARY TRANSTHYRETIN AMYLOIDOSIS MARKET, BY TESTS, 2021-2030 (USD THOUSAND) 60
TABLE 43 SAUDI ARABIA IMAGING TEST IN HEREDITARY TRANSTHYRETIN AMYLOIDOSIS MARKET, BY TYPE, 2021-2030 (USD THOUSAND) 60
TABLE 44 SAUDI ARABIA NUCLEAR IMAGING IN HEREDITARY TRANSTHYRETIN AMYLOIDOSIS MARKET, BY IMAGING TEST, 2021-2030 (USD THOUSAND) 61
TABLE 45 SAUDI ARABIA BIOPSY IN HEREDITARY TRANSTHYRETIN AMYLOIDOSIS MARKET, BY TYPE, 2021-2030 (USD THOUSAND) 61
TABLE 46 SAUDI ARABIA TREATMENT IN HEREDITARY TRANSTHYRETIN AMYLOIDOSIS MARKET, BY TYPE, 2021-2030 (USD THOUSAND) 61
TABLE 47 SAUDI ARABIA MEDICATIONS IN HEREDITARY TRANSTHYRETIN AMYLOIDOSIS MARKET, BY APPROVAL, 2021-2030 (USD THOUSAND) 61
TABLE 48 SAUDI ARABIA APPROVED MEDICATIONS IN HEREDITARY TRANSTHYRETIN AMYLOIDOSIS MARKET, BY TYPE, 2021-2030 (USD THOUSAND) 62
TABLE 49 SAUDI ARABIA PIPELINE MEDICATIONS IN HEREDITARY TRANSTHYRETIN AMYLOIDOSIS MARKET, BY TYPE, 2021-2030 (USD THOUSAND) 62
TABLE 50 SAUDI ARABIA MEDICATIONS IN HEREDITARY TRANSTHYRETIN AMYLOIDOSIS MARKET, BY MODE OF ACTION, 2021-2030 (USD THOUSAND) 62
TABLE 51 SAUDI ARABIA GENE SILENCER IN HEREDITARY TRANSTHYRETIN AMYLOIDOSIS MARKET, BY TYPE, 2021-2030 (USD THOUSAND) 62
TABLE 52 SAUDI ARABIA MEDICATIONS IN HEREDITARY TRANSTHYRETIN AMYLOIDOSIS MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD THOUSAND) 63
TABLE 53 SAUDI ARABIA PARENTERAL IN HEREDITARY TRANSTHYRETIN AMYLOIDOSIS MARKET, BY TYPE, 2021-2030 (USD THOUSAND) 63
TABLE 54 SAUDI ARABIA HEREDITARY TRANSTHYRETIN AMYLOIDOSIS MARKET, BY GENE VARIATION, 2021-2030 (USD THOUSAND) 63
TABLE 55 SAUDI ARABIA HEREDITARY TRANSTHYRETIN AMYLOIDOSIS MARKET, BY GENDER, 2021-2030 (USD THOUSAND) 63
TABLE 56 SAUDI ARABIA HEREDITARY TRANSTHYRETIN AMYLOIDOSIS MARKET, BY INDICATION, 2021-2030 (USD THOUSAND) 64
TABLE 57 SAUDI ARABIA POLYNEUROPATHY (ATTR-PN) IN HEREDITARY TRANSTHYRETIN AMYLOIDOSIS MARKET, BY STAGES, 2021-2030 (USD THOUSAND) 64
TABLE 58 SAUDI ARABIA HEREDITARY TRANSTHYRETIN AMYLOIDOSIS MARKET, BY END USER, 2021-2030 (USD THOUSAND) 64
TABLE 59 SAUDI ARABIA HEREDITARY TRANSTHYRETIN AMYLOIDOSIS MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD THOUSAND) 65
TABLE 60 U.A.E HEREDITARY TRANSTHYRETIN AMYLOIDOSIS MARKET, BY DIAGNOSIS AND TREATMENT, 2021-2030 (USD THOUSAND) 65
TABLE 61 U.A.E DIAGNOSIS IN HEREDITARY TRANSTHYRETIN AMYLOIDOSIS MARKET, BY TESTS, 2021-2030 (USD THOUSAND) 65
TABLE 62 U.A.E IMAGING TEST IN HEREDITARY TRANSTHYRETIN AMYLOIDOSIS MARKET, BY TYPE, 2021-2030 (USD THOUSAND) 65
TABLE 63 U.A.E NUCLEAR IMAGING IN HEREDITARY TRANSTHYRETIN AMYLOIDOSIS MARKET, BY IMAGING TEST, 2021-2030 (USD THOUSAND) 66
TABLE 64 U.A.E BIOPSY IN HEREDITARY TRANSTHYRETIN AMYLOIDOSIS MARKET, BY TYPE, 2021-2030 (USD THOUSAND) 66
TABLE 65 U.A.E TREATMENT IN HEREDITARY TRANSTHYRETIN AMYLOIDOSIS MARKET, BY TYPE, 2021-2030 (USD THOUSAND) 66
TABLE 66 U.A.E MEDICATIONS IN HEREDITARY TRANSTHYRETIN AMYLOIDOSIS MARKET, BY APPROVAL, 2021-2030 (USD THOUSAND) 66
TABLE 67 U.A.E APPROVED MEDICATIONS IN HEREDITARY TRANSTHYRETIN AMYLOIDOSIS MARKET, BY TYPE, 2021-2030 (USD THOUSAND) 67
TABLE 68 U.A.E PIPELINE MEDICATIONS IN HEREDITARY TRANSTHYRETIN AMYLOIDOSIS MARKET, BY TYPE, 2021-2030 (USD THOUSAND) 67
TABLE 69 U.A.E MEDICATIONS IN HEREDITARY TRANSTHYRETIN AMYLOIDOSIS MARKET, BY MODE OF ACTION, 2021-2030 (USD THOUSAND) 67
TABLE 70 U.A.E GENE SILENCER IN HEREDITARY TRANSTHYRETIN AMYLOIDOSIS MARKET, BY TYPE, 2021-2030 (USD THOUSAND) 67
TABLE 71 U.A.E MEDICATIONS IN HEREDITARY TRANSTHYRETIN AMYLOIDOSIS MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD THOUSAND) 68
TABLE 72 U.A.E PARENTERAL IN HEREDITARY TRANSTHYRETIN AMYLOIDOSIS MARKET, BY TYPE, 2021-2030 (USD THOUSAND) 68
TABLE 73 U.A.E HEREDITARY TRANSTHYRETIN AMYLOIDOSIS MARKET, BY GENE VARIATION, 2021-2030 (USD THOUSAND) 68
TABLE 74 U.A.E HEREDITARY TRANSTHYRETIN AMYLOIDOSIS MARKET, BY GENDER, 2021-2030 (USD THOUSAND) 68
TABLE 75 U.A.E HEREDITARY TRANSTHYRETIN AMYLOIDOSIS MARKET, BY INDICATION, 2021-2030 (USD THOUSAND) 69
TABLE 76 U.A.E POLYNEUROPATHY (ATTR-PN) IN HEREDITARY TRANSTHYRETIN AMYLOIDOSIS MARKET, BY STAGES, 2021-2030 (USD THOUSAND) 69
TABLE 77 U.A.E HEREDITARY TRANSTHYRETIN AMYLOIDOSIS MARKET, BY END USER, 2021-2030 (USD THOUSAND) 69
TABLE 78 U.A.E HEREDITARY TRANSTHYRETIN AMYLOIDOSIS MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD THOUSAND) 70
TABLE 79 EGYPT HEREDITARY TRANSTHYRETIN AMYLOIDOSIS MARKET, BY DIAGNOSIS AND TREATMENT, 2021-2030 (USD THOUSAND) 70
TABLE 80 EGYPT DIAGNOSIS IN HEREDITARY TRANSTHYRETIN AMYLOIDOSIS MARKET, BY TESTS, 2021-2030 (USD THOUSAND) 70
TABLE 81 EGYPT IMAGING TEST IN HEREDITARY TRANSTHYRETIN AMYLOIDOSIS MARKET, BY TYPE, 2021-2030 (USD THOUSAND) 70
TABLE 82 EGYPT NUCLEAR IMAGING IN HEREDITARY TRANSTHYRETIN AMYLOIDOSIS MARKET, BY IMAGING TEST, 2021-2030 (USD THOUSAND) 71
TABLE 83 EGYPT BIOPSY IN HEREDITARY TRANSTHYRETIN AMYLOIDOSIS MARKET, BY TYPE, 2021-2030 (USD THOUSAND) 71
TABLE 84 EGYPT TREATMENT IN HEREDITARY TRANSTHYRETIN AMYLOIDOSIS MARKET, BY TYPE, 2021-2030 (USD THOUSAND) 71
TABLE 85 EGYPT MEDICATIONS IN HEREDITARY TRANSTHYRETIN AMYLOIDOSIS MARKET, BY APPROVAL, 2021-2030 (USD THOUSAND) 71
TABLE 86 EGYPT APPROVED MEDICATIONS IN HEREDITARY TRANSTHYRETIN AMYLOIDOSIS MARKET, BY TYPE, 2021-2030 (USD THOUSAND) 72
TABLE 87 EGYPT PIPELINE MEDICATIONS IN HEREDITARY TRANSTHYRETIN AMYLOIDOSIS MARKET, BY TYPE, 2021-2030 (USD THOUSAND) 72
TABLE 88 EGYPT MEDICATIONS IN HEREDITARY TRANSTHYRETIN AMYLOIDOSIS MARKET, BY MODE OF ACTION, 2021-2030 (USD THOUSAND) 72
TABLE 89 EGYPT GENE SILENCER IN HEREDITARY TRANSTHYRETIN AMYLOIDOSIS MARKET, BY TYPE, 2021-2030 (USD THOUSAND) 72
TABLE 90 EGYPT MEDICATIONS IN HEREDITARY TRANSTHYRETIN AMYLOIDOSIS MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD THOUSAND) 73
TABLE 91 EGYPT PARENTERAL IN HEREDITARY TRANSTHYRETIN AMYLOIDOSIS MARKET, BY TYPE, 2021-2030 (USD THOUSAND) 73
TABLE 92 EGYPT HEREDITARY TRANSTHYRETIN AMYLOIDOSIS MARKET, BY GENE VARIATION, 2021-2030 (USD THOUSAND) 73
TABLE 93 EGYPT HEREDITARY TRANSTHYRETIN AMYLOIDOSIS MARKET, BY GENDER, 2021-2030 (USD THOUSAND) 73
TABLE 94 EGYPT HEREDITARY TRANSTHYRETIN AMYLOIDOSIS MARKET, BY INDICATION, 2021-2030 (USD THOUSAND) 74
TABLE 95 EGYPT POLYNEUROPATHY (ATTR-PN) IN HEREDITARY TRANSTHYRETIN AMYLOIDOSIS MARKET, BY STAGES, 2021-2030 (USD THOUSAND) 74
TABLE 96 EGYPT HEREDITARY TRANSTHYRETIN AMYLOIDOSIS MARKET, BY END USER, 2021-2030 (USD THOUSAND) 74
TABLE 97 EGYPT HEREDITARY TRANSTHYRETIN AMYLOIDOSIS MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD THOUSAND) 75
TABLE 98 ISRAEL HEREDITARY TRANSTHYRETIN AMYLOIDOSIS MARKET, BY DIAGNOSIS AND TREATMENT, 2021-2030 (USD THOUSAND) 75
TABLE 99 ISRAEL DIAGNOSIS IN HEREDITARY TRANSTHYRETIN AMYLOIDOSIS MARKET, BY TESTS, 2021-2030 (USD THOUSAND) 75
TABLE 100 ISRAEL IMAGING TEST IN HEREDITARY TRANSTHYRETIN AMYLOIDOSIS MARKET, BY TYPE, 2021-2030 (USD THOUSAND) 75
TABLE 101 ISRAEL NUCLEAR IMAGING IN HEREDITARY TRANSTHYRETIN AMYLOIDOSIS MARKET, BY IMAGING TEST, 2021-2030 (USD THOUSAND) 76
TABLE 102 ISRAEL BIOPSY IN HEREDITARY TRANSTHYRETIN AMYLOIDOSIS MARKET, BY TYPE, 2021-2030 (USD THOUSAND) 76
TABLE 103 ISRAEL TREATMENT IN HEREDITARY TRANSTHYRETIN AMYLOIDOSIS MARKET, BY TYPE, 2021-2030 (USD THOUSAND) 76
TABLE 104 ISRAEL MEDICATIONS IN HEREDITARY TRANSTHYRETIN AMYLOIDOSIS MARKET, BY APPROVAL, 2021-2030 (USD THOUSAND) 76
TABLE 105 ISRAEL APPROVED MEDICATIONS IN HEREDITARY TRANSTHYRETIN AMYLOIDOSIS MARKET, BY TYPE, 2021-2030 (USD THOUSAND) 77
TABLE 106 ISRAEL PIPELINE MEDICATIONS IN HEREDITARY TRANSTHYRETIN AMYLOIDOSIS MARKET, BY TYPE, 2021-2030 (USD THOUSAND) 77
TABLE 107 ISRAEL MEDICATIONS IN HEREDITARY TRANSTHYRETIN AMYLOIDOSIS MARKET, BY MODE OF ACTION, 2021-2030 (USD THOUSAND) 77
TABLE 108 ISRAEL GENE SILENCER IN HEREDITARY TRANSTHYRETIN AMYLOIDOSIS MARKET, BY TYPE, 2021-2030 (USD THOUSAND) 77
TABLE 109 ISRAEL MEDICATIONS IN HEREDITARY TRANSTHYRETIN AMYLOIDOSIS MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD THOUSAND) 78
TABLE 110 ISRAEL PARENTERAL IN HEREDITARY TRANSTHYRETIN AMYLOIDOSIS MARKET, BY TYPE, 2021-2030 (USD THOUSAND) 78
TABLE 111 ISRAEL HEREDITARY TRANSTHYRETIN AMYLOIDOSIS MARKET, BY GENE VARIATION, 2021-2030 (USD THOUSAND) 78
TABLE 112 ISRAEL HEREDITARY TRANSTHYRETIN AMYLOIDOSIS MARKET, BY GENDER, 2021-2030 (USD THOUSAND) 78
TABLE 113 ISRAEL HEREDITARY TRANSTHYRETIN AMYLOIDOSIS MARKET, BY INDICATION, 2021-2030 (USD THOUSAND) 79
TABLE 114 ISRAEL POLYNEUROPATHY (ATTR-PN) IN HEREDITARY TRANSTHYRETIN AMYLOIDOSIS MARKET, BY STAGES, 2021-2030 (USD THOUSAND) 79
TABLE 115 ISRAEL HEREDITARY TRANSTHYRETIN AMYLOIDOSIS MARKET, BY END USER, 2021-2030 (USD THOUSAND) 79
TABLE 116 ISRAEL HEREDITARY TRANSTHYRETIN AMYLOIDOSIS MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD THOUSAND) 80
TABLE 117 REST OF MIDDLE EAST AND AFRICA HEREDITARY TRANSTHYRETIN AMYLOIDOSIS MARKET, BY DIAGNOSIS AND TREATMENT, 2021-2030 (USD THOUSAND) 80

LIST OF FIGURES

FIGURE 1 MIDDLE EAST AND AFRICA HEREDITARY TRANSTHYRETIN AMYLOIDOSIS MARKET: SEGMENTATION 19
FIGURE 2 MIDDLE EAST AND AFRICA HEREDITARY TRANSTHYRETIN AMYLOIDOSIS MARKET: DATA TRIANGULATION 21
FIGURE 3 MIDDLE EAST AND AFRICA HEREDITARY TRANSTHYRETIN AMYLOIDOSIS MARKET: DROC ANALYSIS 22
FIGURE 4 MIDDLE EAST AND AFRICA HEREDITARY TRANSTHYRETIN AMYLOIDOSIS MARKET: REGIONAL VS COUNTRY MARKET ANALYSIS 23
FIGURE 5 MIDDLE EAST AND AFRICA HEREDITARY TRANSTHYRETIN AMYLOIDOSIS MARKET: COMPANY RESEARCH ANALYSIS 23
FIGURE 6 MIDDLE EAST AND AFRICA HEREDITARY TRANSTHYRETIN AMYLOIDOSIS MARKET: INTERVIEW DEMOGRAPHICS 25
FIGURE 7 MIDDLE EAST AND AFRICA HEREDITARY TRANSTHYRETIN AMYLOIDOSIS MARKET: DBMR MARKET POSITION GRID 26
FIGURE 8 MIDDLE EAST AND AFRICA HEREDITARY TRANSTHYRETIN AMYLOIDOSIS MARKET: MARKET END-USER COVERAGE GRID 27
FIGURE 9 MIDDLE EAST AND AFRICA HEREDITARY TRANSTHYRETIN AMYLOIDOSIS MARKET: VENDOR SHARE ANALYSIS 28
FIGURE 10 MIDDLE EAST AND AFRICA HEREDITARY TRANSTHYRETIN AMYLOIDOSIS MARKET: SEGMENTATION 31
FIGURE 11 RISING PREVALENCE OF HEREDITARY TRANSTHYRETIN AMYLOIDOSIS IS EXPECTED TO DRIVE THE MIDDLE EAST AND AFRICA HEREDITARY TRANSTHYRETIN AMYLOIDOSIS MARKET GROWTH IN THE FORECAST PERIOD 32
FIGURE 12 THE DIAGNOSIS SEGMENT IS EXPECTED TO ACCOUNT FOR THE LARGEST SHARE OF THE MIDDLE EAST AND AFRICA HEREDITARY TRANSTHYRETIN AMYLOIDOSIS MARKET IN 2023 AND 2030 32
FIGURE 13 DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES OF THE MIDDLE EAST AND AFRICA HEREDITARY TRANSTHYRETIN AMYLOIDOSIS MARKET 39
FIGURE 14 MIDDLE EAST AND AFRICA HEREDITARY TRANSTHYRETIN AMYLOIDOSIS MARKET: SNAPSHOT (2022) 48
FIGURE 15 MIDDLE EAST AND AFRICA HEREDITARY TRANSTHYRETIN AMYLOIDOSIS MARKET: COMPANY SHARE 2022 (%) 81